International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 1192-1195 www.ijprajournal.com ISSN: 2456-4494

Molecular Docking, Elucidation of Pharmacophore and Synergistic Profiling of Synthetic and Herbal Biologically Active Entities, As a Potential Dipeptidyl Peptidase-4 Inhibitor against Type-2 Diabetes

[1]Priyanka Vishwakarma, [2]Divesh Tripathi, [3]Hritikesh Vhatkar, [4]Amit Yadav, [5]Nikita Yadav

[12345]*St Wilfred Institute of Pharmacy,Navi Mumbai, Panvel*

Date of Submission: 28-05-2025 Date of Acceptance: 08-06-2025

ABSTRACT: Type 2 diabetes stands as the leading kind of the condition, with worldwide frequence rates growing as a matter of transnational concern. The mileage of DPP- 4 impediments as drug to dull insulins, including GLP- 1 and GIP, is adding at a rapid-fire pace. The ideal of this study evaluates G.Uralensis DPP- 4 inhibition eventuality and examines how EGCG from tea and black tea affects diabetes control(1).The development dihydropyrimidine phthalimide mongrels serves as a means to help the diabetes-controlling enzyme Dipeptidyl Peptidase- four. The enzyme DPP- IV, responsible for managing type 2 diabetes, is blocked through natural substances deduced from piperazine. The exploration examines the goods of zygophyllum sp(2). Substances on DPP- 4 and nascence- amylase, both being important enzymes related to diabetes operation Virtual webbing styles together with QSAR artificial intelligence procedures help experimenters in relating particular DPP- 4 impediments. The type 2 diabetes drug sitagliptin functions as an effective DPP- 4 asset, which inhibits GLP- 1 declination processes(3).

KEYWORDS: GLP- 1(Glucagon- Like Peptide-1), GIP (Gastric Inhibitory Polypeptide), G. Uralensis, EGCG (Epigal locatechin Gallate), Zygophyllum sp, QSAR (Quantitative Structure-exertion Relationship)

I. INTRODUCTION

Recent studies revealed that diabetes mellitus case figures reached 463 million in 2019 before projected to grow to 700 million cases by 2045(4).Type 2 diabetes mellitus represents the predominant diabetes subtype affecting around 90 of cases since it features insulin resistance and imperfect insulin stashing combined with enduring high blood glucose situations. High blood glucose causes micro and macrovascular complications through a procedure that results in neuropathy and nephropathy and retinopathy and cardiovascular conditions(5). The current blood sugar operation options fail to produce satisfactory results because medicine- convinced side goods produce complications that lead to wrong remedial yield from being strategies. expansive studies show that DPP- 4 inhibition represents a promising remedial approach because it manages glucose homeostasis and energy metabolism(6) Incretin hormones witness rapid-fire corruption by DPP- 4 following their release through natural stashing(7). The inhibition of DPP- 4 extends incretin hormone exertion so DPP- 4 impediments serve as promising drug options for treating T2DM. The DPP- 4i medicines sitagliptin and vildagliptin together with saxagliptin and teneligliptin boost insulin stashing which effectively controls blood sugar without driving hypoglycemia or weight gain(8). Exploration indicates that DPP- 4 impediments laboriously share in maintaining body energy balance and controlling adipose towel cell exertion. mortal adipose towel appears in three major towel forms. The main function of White adipose towel(WAT) is energy storehouse. The thermoregulation process of energy expenditure occurs through brown adipose towel which maintains operations through sundering protein 1(UCP1). Cold temperatures and β- adrenergic activators stimulate the development of faceless adipocytes which arise as thermogenic cells within WAT during the browning process. Research demonstrates that inhibiting DPP- 4 stimulates both faceless adipose towel conformation and white adipose towel browning which leads to lesser energy operation and impunity against high- fat diet rotundity(9). The junking of DPP- 4 enzyme function through mouse model studies

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 1192-1195 www.ijprajournal.com ISSN: 2456-4494

demonstrates that cells come more metabolically flexible while their mitochondrial exertion and oxygen consumption rates contemporaneously raise. DPP- 4 impediments parade remedial benefits that surpass glycemic control because exploration points to their capability to cover the heart along with reducing inflammation and regulating vulnerable responses. New exploration shows that particular impediments can cover both the cardiovascular system and liver as well as feathers which expands their practical utility for medical operations(9). Clinical issues show DPP- 4 impediments give effective results yet exploration connects specific medicines to pancreatitis and heart failure responses and common pain complaints bettered coming- generation DPP- 4 impediments need to reach the request because they must give better safety measures together with stronger remedial action(4) DPP- 4 impediments parade remedial benefits that surpass glycemic control because exploration points to their capability to cover the heart along with reducing inflammation and regulating vulnerable responses. New exploration shows that particular impediments can cover both the cardiovascular system and liver as well as feathers which expands their practical utility for medical operations. Clinical issues show DPP- 4 impediments give effective results yet exploration connects specific medicines to pancreatitis and heart failure responses and common pain complaints bettered coming- generation DPP- 4 impediments need to reach the request because they must give better safety measures together with stronger remedial action. (7) The exploration field has turned toward natural bioactive composites as implicit backups for DPP- 4 impediments(1). Research has estimated Marine organisms and medicinal shops and food- deduced peptides for their capability to inhibit DPP- 4 exertion. Promising DPP- 4 inhibitory parcels have been set up in fish muscle hydrolysates alongside dairy peptides according to which provides a safer sustainable option compared to synthetic drugs. The discovery of DPP- 4 inhibiting parcels among factory- deduced flavonoids and alkaloids strengthens the remedial eventuality of phytochemicals in Type 2 Diabetes Mellitus(T2DM)(2)

DPP- 4 impediments still face pharmacokinetic issues similar asnon-specific metabolism, renal excretion variability, and metabolic insecurity – these are issues that need to be addressed. To break these problems, a wide range of structural variations on heterocyclic pulpits like pyrimidines and phthalimides have been explored, and as a result, largely picky DPP- 4 impediments have been developed with better bioavailability (10)likewise, there's a great eventuality in inhibition design of binary – target impediments which would spark GLP- 1 receptors and inhibit DPP- 4. medicine convinced DPP- 4 inhibition has gained fresh attention due to new medicine repurposing approaches. In silico webbing ways have revealed a number of being FDA approved drugs to retain DPP- 4 inhibition exertion, which would prop in the development of new medicines. operation of structural similarity searching have enabled the identification of several new impediments that parade remarkable list to the DPP- 4 active point (11)DPP- 4 asset drug uses perfection drug ways which show increased significance through advancing exploration. significance as exploration advances. Croakers can use DPP- 4 impediments singly to optimize patient issues. The case-specific metabolic profile allows both better drug performance and dropped adverse goods. The treatment considers both patient genetics and their enzyme system and medicine immersion patterns. DPP- 4 remedy is not limited to the treatment of diabetes only but has remedial operations in the operation of other diseases like rotundity, metabolic pattern, and cardiovascular affections. Some studies suggest that the DPP- 4 impediments may have anti-inflammatory goods through unresistant mechanisms of vulnerable cell modulation or reduction of oxidative stress labels(10). As exploration continues to advance, perfection drug approaches will decreasingly play a part in DPP-4 asset remedy. Case-specific metabolic profiling, integrating inheritable, enzymatic, and pharmacokinetic data, might allow for substantiated administration of DPP- 4 impediments to optimize efficacity and minimize adverse goods. Besides pharmaceutical interventions, salutary differences and functional foods are being delved as implicit augmenters of endogenous incret in exertion(12).Exploring nutritive strategies that round DPP- 4 inhibition may further optimize T2DM operation and reduce medicine reliance. This has been followed by the integration of pharmacological, biochemical, and computational exploration into DPP- 4's multifaceted part in metabolism, which continues to expand our understanding(9)(13)Current studies are enriching coming- generation impediments, exploring indispensable remedial agents, and perfecting clinical issues. DPP- 4 impediments in the end represent one of the backbones in current diabetes treatment, fastening glucose and energy

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 1192-1195 www.ijprajournal.com ISSN: 2456-4494

metabolism(14).Arising advancements in medicine discovery, metabolic wisdom and substantiated drug will only increase the translational pledge of DPP- 4 inhibition and have counteraccusations for new treatment paradigms in metabolic conditions(15)

II. MATERIAL METHODS

Analyses of DPP- IV impediments through bus wharf 4.0 molecular docking trials were conducted on a Linux system which boasted Intel Core i5 processors.

1. Preparation of Ligands Experimenters designed DPP- IV impediments – Using Chem Draw Ultra 7.0 as the primary design Platform. The docking simulations used the PDBQT format to store structures which were optimized through AM1 methodology.
2. Preparation of the Protein: The DPP- IV protein structure(PDB ID Experimenters recaptured the DPP- IV structure(PDB ID 3F8S) from the Protein Data Bank. bus wharf Tools reused the protein by removing water motes also adding hydrogen tittles and assigning infinitesimal charges.
3. Docking Procedure: The experimenters defined the docking grid to contain a 40 x 40 x 40 Å space that centre on the enzyme's active point. We assay different conformations of each ligand to perform the computations.
4. Confirmation of Docking: Re-docking trials vindicated the methodology by reproducing results showing 0.71 – 0.74 Å RMSD values for a known ligand which demonstrated the docking system's trust ability.

III. RESULT

DPP-4 inhibitors like sitagliptin, vildagliptin, saxagliptin, and teneligliptin help control blood sugar without causing low blood sugar or weight gain. They also have benefits beyond sugar control such as possible heart protection fighting inflammation, and changing immune responses.(8,14,16)

The study used several computer-based techniques, including:
- Auto Dock 4.0 to simulate how molecules fit together
- Chem Draw Ultra 7.0 to design new compounds
- AM1 method to improve structures
- QSAR (Quantitative Structure-Activity Relationship) to analyse data

Scientists applied these methods to look at both lab-made and natural DPP-4 inhibitors. The research uncovered various compounds that control blood sugar well and block DPP-4. This includes: Compounds from Glycyrrhiza uralensis, Epigallocatechin Gallate (EGCG), Inhibitors with a pyrimidine base, Thiazolopyrimidine derivatives

- Mixed compounds Comp70, Quinoxaline derivatives(17)

The study also looked at natural bioactive compounds as potential DPP-4 inhibitors, including sea creatures medicinal plants, and food-derived peptides. Fish muscle hydrolysates, dairy peptides, and plant flavonoids and alkaloids showed promising DPP-4 inhibitory properties(18)

IV. CONCLUSION

Multiple Synthetic and Natural DPP- 4 Impediments Have Shown Successful Performance intheoperation of Type 2 Diabetes According to Test Results. Several composites from Glycyrrhiza Uralensis, Epigallocatechin Gallaten (EGCG), Pyrimidine- Grounded Impediments, Thiazolopyrimidine derivations, mongrel composites, Comp70, CH0002, And Quinoxaline derivations Have Demonstrated Successful Blood Glucose Control and Strong Inhibition At DPP- 4 Receptors(1,9,14,15). Experimenters Should Study the goods of DPP4 Receptor Agonists to Establish Proper Assessments. The important DPP- 4 List parcels of Different specifics Support Pharmaceutical metamorphoses for Their Use(13) The Study Of DPP- 4 Asset relations with Receptors and Functional Changes and Experimental Results Allows Scientists to Establish Meaningful remedial Advantages.

REFERNECES

[1]. Shaikh S, Ali S, Lim JH, Chun HJ, Ahmad K, Ahmad SS, et al. Dipeptidyl peptidase-4 inhibitory potentials of Glycyrrhiza uralensis and its bioactive compounds licochalcone A and licochalcone B: An in silico and in vitro study. Front Mol Biosci. 2022 Sep 30;9:1024764.
[2]. Arbi B, Bouchentouf S, EL-Shazly M. Investigation of the Potential Antidiabetic Effect of Zygophyllum Sp. byStudying the Interaction of its Chemical Compounds with Alpha-Amylaseand DPP-4 Enzymes using a Molecular Docking Approach.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 1192-1195 www.ijprajournal.com ISSN: 2456-4494

Curr Enzyme Inhib. 2023 Aug 8;19(2):100–8.

[3]. Al- masri IM, Mohammad MK, Taha MO. Discovery of DPP IV Inhibitors by Pharmacophore Modeling and QSAR Analysis followed by in silico Screening. ChemMedChem. 2008 Nov 17;3(11):1763–79.

[4]. Istrate D, Bora A, Crisan L. A First Attempt to Identify Repurposable Drugs for Type 2 Diabetes: 3D-Similarity Search and Molecular Docking. In: The 24th International Electronic Conference on Synthetic Organic Chemistry [Internet]. MDPI; 2020 [cited 2025 Jun 2]. p. 7. Available from: https://www.mdpi.com/2673-4583/3/1/7

[5]. Ahmadieh H, Azar ST. The role of incretin-based therapies in prediabetes: A review. Prim Care Diabetes. 2014 Dec;8(4):286–94.

[6]. Kang NS, Ahn JH, Kim SS, Chae CH, Yoo SE. Docking-based 3D-QSAR study for selectivity of DPP4, DPP8, and DPP9 inhibitors. Bioorg Med Chem Lett. 2007 Jul;17(13):3716–21.

[7]. Takeda K, Sawazaki H, Takahashi H, Yeh Y, Jheng H, Nomura W, et al. The dipeptidyl peptidase- 4 (DPP - 4) inhibitor teneligliptin enhances brown adipose tissue function, thereby preventing obesity in mice. FEBS Open Bio. 2018 Nov;8(11):1782–93.

[8]. Ahrén B. Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin.

[9]. Jha V, Bhadoriya KS. Synthesis, pharmacological evaluation and molecular docking studies of pyrimidinedione based DPP-4 inhibitors as antidiabetic agents. J Mol Struct. 2018 Apr;1158:96–105.

[10]. Mourad AAE, Khodir AE, Saber S, Mourad MAE. Novel Potent and Selective DPP-4 Inhibitors: Design, Synthesis and Molecular Docking Study of Dihydropyrimidine Phthalimide Hybrids. Pharmaceuticals. 2021 Feb 11;14(2):144.

[11]. Lolok N, Ramadhan DSF, Sumiwi SA, Sahidin I, Levita J. MOLECULAR DOCKING OF B-SITOSTEROL AND STIGMASTEROL ISOLATED FROM Morinda citrifolia WITH αAMYLASE, α-GLUCOSIDASE, DIPEPTIDYLPEPTIDASE-IV, AND PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-y. Rasayan J Chem. 2022;15(01):20–30.

[12]. Sigal RJ, Kenny GP, Wasserman DH, Castaneda-Sceppa C, White RD. Physical Activity/Exercise and Type 2 Diabetes. Diabetes Care. 2006 Jun 1;29(6):1433–8.

[13]. Hermansyah O, Bustamam A, Yanuar A. Virtual screening of dipeptidyl peptidase-4 inhibitors using quantitative structure–activity relationship-based artificial intelligence and molecular docking of hit compounds. Comput Biol Chem. 2021 Dec;95:107597.

[14]. Kishimoto M. Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes. Diabetes Metab Syndr Obes Targets Ther. 2013 May;187.

[15]. Kumar S, Singla RK, Garg A. Docking Studies of Epigallocatechin Gallate as Natural DPP-IV Inhibitor. In: Proceedings of MOL2NET 2019, International Conference on Multidisciplinary Sciences, 5th edition [Internet]. Sciforum.net: MDPI; 2019 [cited 2025 Jun 2]. p. 6241. Available from: http://sciforum.net/conference/mol2net-05/paper/6241

[16]. Syam YM, Anwar MM, Abd El-Karim SS, Elseginy SA, Essa BM, Sakr TM. New quinoxaline compounds as DPP-4 inhibitors and hypoglycemics: design, synthesis, computational and bio-distribution studies. RSC Adv. 2021;11(58):36989–7010.

[17]. Sharma M, Gupta M, Singh D, Kumar M, Kaur P. Synthesis, Evaluation and Molecular Docking of Thiazolopyrimidine Derivatives as Dipeptidyl Peptidase IV Inhibitors. Chem Biol Drug Des. 2012 Dec;80(6):918–28.

[18]. Shah BM, Modi P, Trivedi P. Pharmacophore- based virtual screening, 3D- QSAR, molecular docking approach for identification of potential dipeptidyl peptidase IV inhibitors. J Biomol Struct Dyn. 2021 Mar 31;39(6):2021–43.